Germany-based biotech ATAI Life Sciences, which aims to grow into a major global biopharmaceutical player by following a company buy-and-build approach, has acquired a majority stake in Perception Neuroscience.
The latter is a New York company focused on developing innovative therapies in neuropsychiatry and with the NMDA antagonist arketamine (PCN 101), a single isomer of ketamine, as its lead candidate.
Arketamine belongs to a new generation of glutamate receptor modulators with the potential for rapid acting antidepressant (RAAD) activity and anti-suicidal effects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze